Drug-Resistant Tuberculosis
Cross-source consensus on Drug-Resistant Tuberculosis from 1 sources and 3 claims.
1 sources · 3 claims
Uses
How it works
Background
Highlighted claims
- The proportion of MDR/XDR-TB in Kenya is relatively low at 7.1% in 2023, limiting the number of drug-resistance-attributable treatment failures that can be studied separately. — Evaluating the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis: protocol for a prospective longitudinal study in Nairobi, Kenya
- Drug-resistant and drug-susceptible TB are managed according to routine clinical practice and Kenya national guidelines; the study does not influence treatment decisions. — Evaluating the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis: protocol for a prospective longitudinal study in Nairobi, Kenya
- Drug susceptibility results are documented and may be used as covariates in exploratory analyses, but the primary analysis is not stratified by resistance status. — Evaluating the PATHFAST TB LAM Ag assay as a treatment monitoring tool for pulmonary tuberculosis: protocol for a prospective longitudinal study in Nairobi, Kenya